JDRF - Juvenile Diabetes Research Foundation

JDRF funded trails at Cambridge University have shown that an artificial pancreas dramatically reduces the risk of potentially deadly hypoglycemia.

Published today in the respected journal The Lancet, JDRF-funded researchers developed and successfully tested an automated management system, which was able to predict and prevent blood sugar fluctuations. Dramatic blood sugar drops, or hypoglycemia, have immediate and often devastating consequences and have an enormous impact on both individuals and families living with type 1 diabetes.

Read more...

In a significant breakthrough for people with diabetes, JDRF has formed a partnership with two international companies to produce an automated diabetes management system to eliminate the need for insulin injections and dramatically reduce the risk of life threatening health complications.

The Juvenile Diabetes Research Foundation has today announced an innovative partnership to develop an automated system to help people with type 1 diabetes better control their disease – the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels.

Read more...

Two major JDRF-funded studies in the US have shown that continuous glucose monitors (CGMs) deliver better diabetes control with regular use for all age groups, while also reducing the frequency of hypoglycemia, or dangerously low blood glucose levels that can lead to coma or death.

The first study showed that regular use of CGMs is the main factor in achieving better diabetes control, rather than the age of people using the monitors, or other demographic, clinical, or psychosocial factors.  The second study showed that people using CGMs were able to achieve good diabetes control while at the same time actually lowering the incidence of hypoglycemia.

Read more...

A JDRF trial shows that continuous glucose monitor (CGM) devices help to maintain tight blood sugar levels whilst lowering the risk of dangerously low blood sugar.

There is extensive research to show that tight blood glucose control is the best way to prevent the onset of type 1 diabetes complications such as kidney failure, retinopathy and heart disease. According to results from the Diabetes Complications and Control Trial, every one point reduction in HbA1C reduces the risk of long-term complications by approximately 40%.

Unfortunately, research has also shown that one of the hurdles to tight blood sugar control is the risk of hypoglycemia – both real and perceived.

Read more...